Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma

被引：0
作者：
Lynch, Emer [1 ]
Duffy, Austin G. [1 ]
Kelly, Ronan J. [2 ]
机构：
[1] Mater Hosp, Dept Med Oncol, Dublin D18 DH50, Ireland
[2] Baylor Univ, Charles A Sammons Canc Ctr, Med Ctr, Dallas, TX 75246 USA
来源：
PHARMACEUTICALS | 2023年 / 16卷 / 01期
关键词：
Gastric cancer; gastro-esophageal adenocarcinoma; immune checkpoint inhibitor; PD-L1; CTLA-4; GASTROESOPHAGEAL JUNCTION CANCER; PLUS CHEMOTHERAPY CHEMO; OPEN-LABEL; T-CELLS; 1ST-LINE PEMBROLIZUMAB; RESECTED ESOPHAGEAL; REGULATORY T; DOUBLE-BLIND; NIVOLUMAB; EFFICACY;
D O I：
10.3390/ph16010102
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
In the West, recent decades have demonstrated an epidemiological trend towards esophago-gastric adenocarcinomas (EGAC), with considerable associated mortality. Historically, chemotherapy has represented the sole systemic treatment option in the advanced EGAC setting, in addition to complementing the role of surgery and radiotherapy in the case of localized disease. Immune checkpoint inhibitors (ICIs) represent a novel systemic therapeutic choice and have revolutionized the management of other malignancies, including melanoma and renal cell carcinomas. This article considers the rationale for ICIs in EGAC, reviews the evidence supporting their role in the current standard of care in EGAC, and briefly considers ongoing trials and future directions for the ICI class in EGAC.
引用
收藏
页数：17
相关论文
共 65 条
  • [1] FRACTION (Fast Real-time Assessment of Combination Therapies in Immu no-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.
    Aanur, Praveen
    Gutierrez, Martin
    Kelly, Ronan Joseph
    Ajani, Jaffer A.
    Ku, Geoffrey Yuyat
    Denlinger, Crystal Shereen
    George, Thomas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Al-Batran SE, 2022, J CLIN ONCOL, V40
  • [3] Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
    Andre, Thierry
    Tougeron, David
    Piessen, Guillaume
    de la Fouchardiere, Christelle
    Louvet, Christophe
    Adenis, Antoine
    Jary, Marine
    Tournigand, Christophe
    Aparicio, Thomas
    Desrame, Jerome
    Lievre, Astrid
    Garcia-Larnicol, Marie-Line
    Pudlarz, Thomas
    Cohen, Romain
    Memmi, Salome
    Vernerey, Dewi
    Henriques, Julie
    Lefevre, Jeremie H.
    Svrcek, Magali
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 255 - +
  • [4] [Anonymous], RAND DOUBL BLIND PLA
  • [5] [Anonymous], Efficacy and safety evaluation of allergen immunotherapy co-administered with omalizumab, an anti-IgE monoclonal antibody
  • [6] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [7] Australasian Gastro-Intestinal Trials Group, RAND PHAS 3 OP LAB S
  • [8] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
    Bang, Y. -J.
    Ruiz, E. Yanez
    Van Cutsem, E.
    Lee, K. -W.
    Wyrwicz, L.
    Schenker, M.
    Alsina, M.
    Ryu, M. -H.
    Chung, H. -C.
    Evesque, L.
    Al-Batran, S. -E.
    Park, S. H.
    Lichinitser, M.
    Boku, N.
    Moehler, M. H.
    Hong, J.
    Xiong, H.
    Hallwachs, R.
    Conti, I.
    Taieb, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (10) : 2052 - 2060
  • [9] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    [J]. GASTRIC CANCER, 2019, 22 (04) : 828 - 837
  • [10] KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Ilson, David H.
    Hyung, Woo Jin
    Strong, Vivian E.
    Goetze, Thorsten Oliver
    Yoshikawa, Takaki
    Tang, Laura H.
    Hwang, Peggy May Tan
    Webb, Nancy
    Adelberg, David
    Shitara, Kohei
    [J]. FUTURE ONCOLOGY, 2019, 15 (09) : 943 - 952
1234567